Redhill Biopharma
RDHL
34 hedge funds and large institutions have $64.8M invested in Redhill Biopharma in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 5 closing their positions.
1,286% more call options, than puts
Call options by funds: $194K | Put options by funds: $14K
41% more capital invested
Capital invested by funds: $45.9M → $64.8M (+$18.9M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
6% less funds holding
Funds holding: 36 → 34 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
+$293K |
| 2 |
Morgan Stanley
New York
|
+$182K |
| 3 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$55.4K |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$39.6K |
| 5 |
Bank of New York Mellon
New York
|
+$39.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.61M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$846K |
| 3 |
O
OrbiMed
New York
|
-$303K |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$277K |
| 5 |
MC
Menta Capital
San Francisco,
California
|
-$206K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PVH
26
Psagot Value Holdings
Tel Aviv,
Israel
| $52K | – | – | – |
|
27
UBS Group
Zurich,
Switzerland
| $41K | +$23.7K | +3 | +150% |
|
28
Bank of America
Charlotte,
North Carolina
| $25K | – | – | – |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| $25K | – | – | – |
|
|
LTFS
30
Ladenburg Thalmann Financial Services
Miami,
Florida
| $18K | +$15.8K | +2 | New |
|
|
FANJ
31
Financial Architects (New Jersey)
Marlton,
New Jersey
| $17K | – | – | – |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $12K | +$7.91K | +1 | New |
|
33
Wells Fargo
San Francisco,
California
| $7K | – | – | – |
|
34
JP Morgan Chase
New York
| $4K | +$7.91K | +1 | New |
|
35
Group One Trading
Chicago,
Illinois
| $3K | -$7.91K | -1 | Closed |
|
|
CG
36
Cutler Group
San Francisco,
California
| $2K | – | – | – |
|
|
O
37
OrbiMed
New York
| – | -$303K | -55 | Closed |
|
|
OAM
38
Oxford Asset Management
Oxford,
United Kingdom
| – | -$138K | -25 | Closed |
|
39
Citadel Advisors
Miami,
Florida
| – | -$101K | -18 | Closed |
|
|
ARTA
40
A.R.T. Advisors
New York
| – | -$71K | -13 | Closed |
|
RDHL Hedge Fund Activity: Q1 2019 in Review
34 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q1 2019, worth a combined $64.8M — up 41% from $45.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of RDHL and 3 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was Ibex Investors, adding an estimated $293K. The largest seller was Millennium Management, cutting an estimated $1.61M.
- 34 institutional investors held Redhill Biopharma (RDHL) as of Q1 2019, down from 36 in Q4 2018.
- Funds reported $64.8M of Redhill Biopharma stock for Q1 2019, up 41% quarter-over-quarter.
- 3 funds opened new Redhill Biopharma positions in Q1 2019 and 5 closed out, a net change of -2 holders.
- The largest Redhill Biopharma buyer in Q1 2019 was Ibex Investors, an estimated $293K added.
- The largest Redhill Biopharma seller in Q1 2019 was Millennium Management, an estimated $1.61M sold.
Based on aggregated 13F filings for Q1 2019.